Spring 2019 | Lexis Practice Advisor's Intellectual Property and Technology

Biosimilar and The Biologics Price Competition and Innovation Act (BPCIA)

1 min

The article introduces biosimilars and the litigation process set up by the BPCIA to facilitate resolution of patent disputes between RPSs and biosimilar manufacturers, and touches on related trends, such as the potential use of inter partes review proceedings by biosimilar manufacturers as an alternative to or in addition to litigation.